Emezin Plus® tablet: Each unit contains meclizine HCI USP 25 mg and pyridoxine HCI USP 50 mg.
Emezin is a combination of meclizine and pyridoxine HCl. Meclizine HCl is a piperazine-derivative antihistamine that is used as an antiemetic. It has antiemetic, anticholinergic and antihistaminic properties. It exhibits its action by an effect on CNS, possibly by its ability to block muscarinic receptors in the brain. It has marked effects in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. It reduces the sensitivity of the labyrinthine apparatus. The site and mechanism of action of meclizine HCl in controlling vertigo from various conditions have not been clearly defined. Pyridoxine HCl (vit-Bg), either alone or combination has been used to prevent nausea and vomiting due to its antiemetic properties.
The fixed-dose combination (FDC) is recommended for oral administration. Nausea & vomiting (including morning sickness in pregnancy): One tablet 1-2 times daily or as directed by physician. Motion sickness: The initial dose is one or two tablets daily, it should be taken one hour prior to journey for protection against motion sickness. Therefore, the dose may be repeated every 24 hours as indicated for the duration of journey. Vertigo: One tablet two times daily or as directed by physician. Labyrinthine and vestibular disturbances: The optimal dose of Meclizine HCl is usually 25 to 100 mg daily in divided doses, depending on the clinical response. Radiation sickness: 50 mg (Meclizine HCl) administered 2 to 12 hours prior to radiation treatment. Pyridoxine (vitamin Bg) has been shown to be safe and effective in dosages of 50 to 200 mg per day.
There may be increased CNS depression when meclizine HCI and pyridoxine HCI is administered concurrently with other CNS depressants, including benzodiazepines, barbiturates, tricyclic antidepressants, opiate agonists, skeletal muscle relaxants, antihistamines, alcohol, tranquilizers. Meclizine HCl can increase the absorption of digoxin by decreasing gastrointestinal motility. MAO inhibitors may prolong and intensify the anticholinergic effects of meclizine HCl.
OVERDOSAGE Symptoms: Extreme excitability, seizure, drowsiness, temporary nerve damage, hallucination. Treatment: Appropriate supportive and symptomatic treatment.
PHARMACEUTICAL PRECAUTION Store at or below 30 °C temperature. Keep away from light and wet place.
Keep out of the reach of children.
. Pyridoxine HCI: Pregnancy category A. Pyridoxine itself is considered safe during pregnancy and has been used in pregnant women without any evidence of fetal harm.
Due to its potential anticholinergic action, patient with asthma, bronchitis, emphysema, enlarged prostate, glaucoma or urinary tract blockade should take meclizine HCI (like other antiemetics) with caution. Although meclizine HCl may excrete into the milk, it causes no harm in nursing babies. Meclizine HCI: Pregnancy category B. Large-scale human studies have not demonstrated adverse fetal effects. It has been suggested that, based on available data, meclizine HCI presents the lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during.
Store at or below 30°C temperature. Keep away from light and wet place. Keep out of the reach of children.